ライブ
LabiotechNew names, new narratives: Why biotechs decide to rebrandPharmaVoiceThe biotech market is rebounding. So where are the executive jobs?FierceBiotechSoligenix axes lymphoma program after phase 3 setback, mulls M&A optionsFierceBiotechBeyond Rigid Platforms: Adaptive Adenoviral Platform De-Risks Development to GMPFierceBiotechHow NEC's AI and oral delivery system are redefining personalized cancer therapyEndpoints NewsLilly puts its stamp at #EHA26 with Jaypirca combo data in CLL, first clinical data from Ajax buyoutBioPharma DiveCeliac disease is entering a new era of therapeutic innovationBioPharma DivePlanning a successful pivot from lab to clinicScience Daily BiotechScientists turned red lettuce green and something surprising happenedEndpoints NewsHMNC Brain Health raises $50M Series B to advance two depression drugseLifeExposure to false cardiac feedback alters pain perception and anticipatory cardiac frequencyeLifeNuclear CK1δ as a critical determinant of PER:CRY complex dynamics and circadian period
Novo Nordisk 2026年4月30日

Novo-Backed Biotech Hemab Raises $301.5 Million in Upsized IPO - Bloomberg.com

Novo-Backed Biotech Hemab Raises $301.5 Million in Upsized IPO - Bloomberg.com

原文
本文は利用できません。元の情報源をご確認ください。